Compare McDonald's Corp (MCD) vs TG Therapeutics Inc (TGTX) Price & Performance

McDonald's (MCD) trades at $273.72, down 0.28% on the day, with a neutral technical signal and strong fundamentals including a 31.72% net margin and consistent earnings beats. The company recently unveiled its 'McDonald's NEXT' growth strategy focusing on automation and menu innovation to drive future performance. Revenue growth remains steady, with 2025 revenue at $26.89 billion.

Outlook is positive with a consensus price target of $322.45 offering 17.8% upside, supported by 60% analyst buy ratings. Risks include inflationary pressures on franchisee margins and high long-term debt of $38.42 billion. The stock presents a value opportunity with stable dividends and strategic initiatives aimed at enhancing competitiveness.

TG Therapeutics (TGTX) trades at $49.66, up 1.02% on the day, with a bearish technical signal and recent earnings misses despite strong revenue growth. The company reported Q2 2026 revenue of $240 million and raised full-year BRIUMVI guidance to $950 million, but net income was impacted by manufacturing investments. Valuation ratios show a high P/E of 18.22 and EV/EBITDA of 56.26, while profitability metrics like ROE of 100.28% remain robust.

Outlook is mixed: strong product demand and raised revenue targets support growth, but earnings volatility and a bearish technical trend pose risks. Analyst consensus is bullish with an $63.75 price target, though legal investigations and competitive pressures require monitoring for stock investors.